SAN DIEGO, May 28, 2020 /PRNewswire/ -- Tocagen Inc.
(Nasdaq: TOCA), historically a clinical-stage, cancer-selective
gene therapy company, announced today that, due to public health
and safety concerns related to the COVID-19 global pandemic,
recommendations and orders from federal, state and local
authorities, and to support the health and well-being of its
stockholders, employees and others, it is changing its special
meeting of stockholders related to its previously announced
proposed merger with Forte Biosciences, Inc. (the "Special
Meeting") to a virtual-only format that will be held via live audio
webcast.
The previously announced date and time of the Special Meeting,
Friday, June 12, 2020, at
9:00 a.m. Pacific Time, has not
changed. Online access to the Special Meeting will be available and
stockholders will not be able to attend the Special Meeting in
person.
Attending the Virtual Meeting as a Stockholder of
Record
Tocagen's stockholders of record as of April 20, 2020 (the "Record Date") can attend the
Special Meeting by registering in advance of the registration
deadline of June 10, 2020 at
5:00 p.m. Eastern Time at
www.proxydocs.com/TOCA, and entering the control number on the
proxy card/voting instruction form previously received.
Instructions on how to connect to the Special Meeting and
participate via the Internet will be provided to you in subsequent
email communications.
Attending the Virtual Meeting as a Beneficial Owner
Tocagen has been advised by Mediant Communications Inc. that
beneficial stockholders as of the Record Date (i.e. shares held in
"street name" through an intermediary, such as a bank or broker),
who want to be able attend the Special Meeting can attend by using
the control number found on the notice and instructions received
from their broker or other nominee and by registering in advance of
the registration deadline of June 10,
2020 at 5:00 p.m. Eastern Time
at www.proxydocs.com/TOCA. Note, however, that you will need a
valid proxy from your broker or nominee if you wish to vote at the
virtual meeting.
Asking Questions
If you are attending the Special Meeting as a stockholder of
record or registered beneficial owner, you can submit questions
during the meeting by using the "Q&A" function in the meeting
portal. Questions can also be submitted in advance of the meeting
during the registration process. Questions submitted in advance of
and at the meeting will be addressed during the meeting as
determined by Tocagen.
Voting Shares
Stockholders of record and registered beneficial owners holding
a valid proxy from their broker or nominee will be able to vote
their shares electronically during the Special Meeting.
Instructions on how to vote while participating in the Special
Meeting live via the Internet will be provided to you in subsequent
email communications after registration, as described above.
Whether or not stockholders plan to virtually attend the
Special Meeting, Tocagen urges them to vote and submit their proxy
in advance of the Special Meeting by one of the methods described
in the proxy materials for the Special Meeting.
The proxy card/voting instruction form included with any proxy
materials previously distributed will not be updated to reflect the
change in location and may continue to be used to vote shares in
connection with the Special Meeting.
List of Stockholders
A list of stockholders of record will be available during the
Special Meeting for inspection by stockholders of record for any
purpose germane to the Special Meeting by following the
instructions received in the email communications described
above.
About Tocagen
Historically, Tocagen was a clinical-stage, cancer-selective
gene therapy company developing broadly applicable product
candidates designed to activate a patient's immune system against
their own cancer. For more information about Tocagen, visit
www.tocagen.com.
View original
content:http://www.prnewswire.com/news-releases/tocagen-announces-change-to-virtual-format-for-special-meeting-of-stockholders-301067275.html
SOURCE Tocagen Inc.